Chloroquine sensitizes biofilms of Candida albicans to antifungal azoles

Brazilian Journal of Infectious Diseases

Volumn 17, Issue 4, 2013, Pages 395-400

  Shinde, Ravikumar Bapurao ^a   Raut, Jayant Shankar ^a   Chauhan, Nitin Mahendra ^a   Karuppayil, Sankunny Mohan ^a  

^a SWAMI RAMANAND TEERTH MARATHWADA UNIVERSITY   (India)

Author keywords

Antifungal; Biofilm; Candida albicans; Chloroquine; Combination; Drug resistance

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; CHLOROQUINE; FLUCONAZOLE; LARIAGO; UNCLASSIFIED DRUG; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BIOFILM; CANDIDA ALBICANS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; FUNGAL MEMBRANE; NONHUMAN; SCANNING ELECTRON MICROSCOPY;

ANTIFUNGAL; BIOFILM; CANDIDA ALBICANS; CHLOROQUINE; COMBINATION; DRUG RESISTANCE;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; AZOLES; BIOFILMS; CANDIDA ALBICANS; CHLOROQUINE; DRUG SYNERGISM; ECHINOCANDINS; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, ELECTRON, SCANNING;

EID: 84880939734     PISSN: 14138670     EISSN: 16784391     Source Type: Journal    
DOI: 10.1016/j.bjid.2012.11.002     Document Type: Article

References (25)

1. Ramage G., Martinez J.P., Lopez-Ribot J.L. Candida biofilms on implanted biomaterials: a clinically significant problem. FEMS Yeast Res 2006, 6:979-986.
2. Kumamoto C.A., Vinces M.D. Alternative Candida albicans life styles: growth on surfaces. Annu Rev Microbiol 2005, 59:113-133.
3. Chandra J., Kuhn D.M., Mukherjee P.K., Hoyer L.L., McCormic T., Ghannoum M.A. Biofilm formation by fungal pathogen Candida albicans: development, architecture and drug resistance. J Bacteriol 2001, 183:5385-5394.
4. Jabra-Rizk M.A., Falkler W.A., Meiller T.F. Fungal biofilms and drug resistance. Emerg Infect Dis 2004, 10:14-19.
5. Aparna M.S., Yadav S. Biofilms: microbes and disease. Braz J Infect Dis 2008, 12:526-530.
6. Nett J.E., Sanchez H., Cain M.T., Andes D.R. Genetic basis of Candida biofilm resistance due to drug-sequestering matrix glucan. J Infect Dis 2010, 202:171-175.
7. Shinde R.B., Raut J.S., Karuppayil S.M. Biofilm formation by Candida albicans on various prosthetic materials and its fluconazole sensitivity: a kinetic study. Mycoscience 2012, 53:220-226.
8. Baillie G.S., Douglas L.J. Matrix polymers of Candida albicans biofilms to antifungal agents. J Antimicrob Chemother 2000, 6:397-403.
9. Mishra N.N., Prasad T., Sharma N., et al. Pathogenicity and drug resistance in Candida albicans and other yeast species a review. Acta Microbiol Immunol Hung 2007, 54:201-235.
10. Spitzer M., Griffiths E., Blakely K.M., et al. Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole. Mol Syst Biol 2011, 7:499.
11. Scheid L.A., Mario D.A.N., Kubiça T.F., Santurio J.M., Alves S.H. In vitro activities of antifungal agents alone and in combination against fluconazole-susceptible and resistant strains of Candida dubliniensis. Braz J Infect Dis 2012, 16:78-81.
12. Slater A.F.G. Chloroquine: mechanism of drug action and resistance in Plasmodium falciparum. Pharm Ther 1993, 57:203-235.
13. Fitch C.D., Chevli R., Kanjananggulpan P., Dutta P., Chevli K., Chou A.C. Intracellular ferriprotoporphyrin IX is a lytic agent. Blood 1983, 62:1165-1168.
14. Mwai L., Ochong E., Abdirahman A., et al. Chloroquine resistance before and after its withdrawal in Kenya. Malaria J 2009, 8:106.
15. Baird J.K. Chloroquine resistance in Plasmodium vivax. Antimicrob Agents Chemother 2004, 48:4075-4083.
16. Savarino A., Lucia M.B., Giordano F., Cauda R. Risks and benefits of chloroquine use in anticancer strategies. Lancet Oncol 2006, 7:792-793.
17. Sotelo J., Briceno E., Lopez-Gonzalez M.A. Adding chloroquine to conventional treatment for glioblastoma multiforme; a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2006, 144:337-343.
18. Weber S.M., Levitz S.M., Harrison T.S. Chloroquine and the fungal phagosome. Curr Opin Microbiol 2000, 3:349-353.
19. Khan M.A., Jabeen R., Nasti T.H., Mohammad O. Enhanced anticryptococcal activity of chloroquine in phosphatidylserine-containing liposomes in a murine model. J Antimicrob Chemother 2005, 55:223-228.
20. Guo Q., Sun S., Yu J., Li Y., Cao L. Synergistic activity of azoles with amiodarone against clinically resistant Candida albicans tested by chequerboard and time-kill methods. J Med Microbiol 2008, 57:457-462.
21. Sun S., Yan L., Guo Q., Shi C., Yu J., Ma L. In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods. Antimicrob Agents Chemother 2008, 52:409-417.
22. Mateus C., Crow S.A., Ahearn D.G. Adherence of Candida albicans to silicone induces immediate enhanced tolerance to fluconazole. Antimicrob Agents Chemother 2004, 48:3358-3366.
23. Uppuluri P., Nett J., Heitman J., Andes D. Synergistic effect of calcineurin inhibitors and Fluconazole against Candida albicans biofilms. Antimicrob Agents Chemother 2008, 52:1127-1132.
24. Achudume A.C. The influence of chloroquine administration on antioxidant levels, oxidant marker and total cholesterol in Wistar rats. Biol Med 2009, 1:39-43.
25. Emerson L.R., Nau M.E., Martin R.K., Kyle D.E., Vahey M., Wirth D.F. Relationship between chloroquine toxicity and iron acquisition in Saccharomyces cerevisiae. Antimicrob Agents Chemother 2002, 46:787-796.